Signal detection methodologies to support effective safety management

Expert Opinion on Drug Safety

Volumn 6, Issue 4, 2007, Pages 451-464

  van Manen, Robbert P ^a   Fram, David ^a   DuMouchel, William ^a  

^a Phase Forward   (United States)

Author keywords

Pharmacovigilance; Product safety; Quantitative signal detection; Risk management

Indexed keywords

ALOSETRON; ASTEMIZOLE; AZARIBINE; BENOXAPROFEN; BROMFENAC; CERIVASTATIN; CISAPRIDE; ENCAINIDE; ETRETINATE; FANOLESOMAB TC 99M; FENFLURAMINE; FLOSEQUINAN; GREPAFLOXACIN; LEVACETYLMETHADOL; MIBEFRADIL; NATALIZUMAB; NOMIFENSINE; PEMOLINE; RAPACURONIUM BROMIDE; ROFECOXIB; SUPROFEN; TEMAFLOXACIN; TERFENADINE; TIENILIC ACID; TROGLITAZONE; VALDECOXIB; ZOMEPIRAC;

ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ATTENTION DEFICIT DISORDER; BAYES THEOREM; BIRTH DEFECT; BLOOD CLOTTING DISORDER; BRAIN INFECTION; BREATHING DISORDER; CARDIOPULMONARY ARREST; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONSTIPATION; DATA BASE; DATA MINING; DEMOGRAPHY; DENOMINATOR BASED SIGNAL SCORE; DENOMINATOR INDEPENDENT SIGNAL SCORE; DEPRESSION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEARTBURN; HEMOLYTIC ANEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFORMATION PROCESSING; IRRITABLE COLON; ISCHEMIC COLITIS; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; MUSCLE INJURY; OPIATE ADDICTION; PAIN; PSORIASIS; QUANTITATIVE ANALYSIS; REVIEW; RISK MANAGEMENT; SIGNAL DETECTION; SKIN DISEASE; STAFF TRAINING; STATISTICAL ANALYSIS; VALVULAR HEART DISEASE; ANIMAL; METHODOLOGY; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; SAFETY; STANDARD;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SAFETY MANAGEMENT;

EID: 34548473335     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.4.451     Document Type: Review

References (75)

1. FOOD AND DRUG ADMINISTRATION: Guidance for Industry. Premarketing Risk Assessment. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), USA March (2005).
2. FOOD AND DRUG ADMINISTRATION: Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), USA Match (2005).
3. FOOD AND DRUG ADMINISTRATION: Guidance for Industry Development and Use of Risk Minimization Action Plans. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), USA March (2005).
4. FDA TASK FORCE ON RISK MANAGEMENT: Report to the FDA Commissioner Managing the Risks from Medical Product Use Creating a Risk Management Framework. US Department of Health and Human Services Food and Drug Administration, USA May (1999).
5. EUROPEAN MEDICINES AGENCY (EMEA): European risk-management strategy: progress to date and next steps EMEA (2005) EMEA/136253/2005.
6. HEADS OF MEDICINES AGENCIES (HMA) MANAGEMENT GROUP: Report of the ad-hoc working group on the progress on implementation of the European risk-management strategy EMEA (2005) HMA-H 3a3.
7. EUROPEAN MEDICINES AGENCY (EMEA): Action plan to further progress the European risk-management strategy EMEA (2005) EMEA/115906/2005/Final.
8. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: E2E: Pharmacovigilance Planning ICH Harmonised Tripartite Guideline (2004). Federal Register (2005) 70(62):16827-16828.
9. CIOMS WORKING GROUP VI: Management of Safety Information. In: Clinical Trials. Council for International Organizations of Medical Sciences, Geneva, Switzerland (2005).
10. WILSON AM, THABANE L, HOLBROOK A: Application of data mining techniques in pharmacovigilance Br. J. Clin. Pharmacol. (2004) 57(2):127-134.
11. ALMENOFF J, TONNING JM, GOULD AL et al.: Perspectives on the use of data mining in pharmacovigilance. Drug Saf. (2005)28(11):981-1007.
12. MEYBOOM RH, EGBERTS AC, EDWARDS IR, HEKSTER YA, DE KONING FH, GRIBNAU FW: Principles of signal detection in pharmacovigilance. Drug Saf. (1997) 16:355-365.
13. ANDREWS E, DOMBECK M: The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiol. Drug Saf. (2004) 13(9):599-608.
14. GANDHI TK, SEGER DL, BATES DW: Identifying drug safety issues: from research to practice. Int. J. Qual Healthcare (2000) 12(1):69-76.
15. MURFF HJ, PATEL VE, HRIPCSAK G, BATES DW: Detecting adverse events for patient safety research: a review of current methodologies. J. Biomed. Informatics (2003) 36:131-143.
16. BACKSTRÖM M, MJÖRNDAL T, DAHLQVIST R: Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol. Drug Saf. (2004) 13:483-487.
17. MARTIN RM, KAPOOR KV, WILTON LV, MANN RD: Underreporting of suspected adverse drug reactions to newly marketed ("black triangle" drugs in general practice: observational study. BMJ (1998) 317(7151):119-120.
18. VAN DER HEIJDEN PG, VAN PUIJENBROEK EP, VAN BUUREN S, VAN DER HOFSTEDE JW: On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Statistics Med. (2002) 21(14):2027-2044.
19. O'NEILL R, SZARFMAN A: Some US Food and Drug Administration Perspectives on Data Mining for Pediatric Safety Assessment. Curr. Therap. Res. (2001) 62(9):650-663.
20. MANTEL N, HANKEY BF: Programmed Analysis of a 2 × 2 Contingency Table. The American Statistician (1971) 25(5):40-44.
21. GREEN MD, FREEDMAN DM, GORDIS L: Reference Guide on Epidemiology. In: Federal Judicial Center Reference Manual on Scientific Evidence. (2000):333-400.
22. ZHANG J, YU KF: What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA (1998) 280(19):1690-1691.
23. MCNUTT LA, WU C, XUE X, HAFNER JP: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am. J. Epidemiol. (2003) 157(10):940-943.
24. UPTON G: Fisher's Exact Test. J. Royal Statist. Soc. A (1992) 155(3):395-402.
25. DUMOUCHEL W: Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. The American Statistician (1999) 53(3):177-202.
26. EVANS SJW, WALLER PC, DAVIS S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. (2001) 10:483-486.
27. VAN PUIJENBROEK EP, DIEMONT WL, VAN GROOTHEEST K: Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. (2003) 26(5):293-301.
28. VAN PUIJENBROEK EP, BATE A, LEUFKENS HGM, LINDQUIST M, ORRE R, EGBERTS ACG: A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. (2002) 11:3-10.
29. EGBERTS ACG, MEYBOOM RHB, VAN PUIJENBROEK EP: Use of measures of disproportionality in pharmacovigilance - three Dutch examples. Drug Saf. (2002) 25(6):453-458.
30. ROTHMAN K, LANES S, SACKS ST: The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. (2004) 13:519-523.
31. WALLER P, VAN PUIJENBROEK EP, EGBERTS ACG, EVANS S: The reporting odds ratio versus the proportional reporting ratio: 'deuce'. Pharmacoepidemiol. Drug Saf. (2004) 13:525-526.
32. AGRESTI A, HITCHCOCK D: Bayesian inference for categorical data analysis: a survey. Technical Report. Department of Statistics, University of Florida, USA (2004).
33. DUMOUCHEL W, PREGIBON D: Empirical Bayes Screening for Multi-item. In: Associations Proceedings of the Conference on Knowledge Discovery and Data. ACM Press, San Diego, CA, USA (2001):67-76.
34. BATE A: The Use of a Bayesian Confidence Propagation Neural Network in Pharmacovigilance. Umeå University, Umeå, Sweden (2003).
35. BATE A, LINDQUIST M, EDWARDS IR et al.: A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. (1998) 54:315-321.
36. BATE A, LINDQUIST M, ORRE R, EDWARDS IR, MEYBOOM RHB: Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur. J. Clin. Pharmacol. (2002) 58:483-490.
37. FRAM D, ALMENOFF JS, DUMOUCHEL W: Empirical Bayesian data mining for discovering patterns in post-marketing drug safety. Proceedings ACM SIGKDD (2003):359-368.
38. SZARFMAN A, MACHADO SG, O'NEILL R: Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. (2002) 25(6):381-392.
39. FOOD AND DRUG ADMINISTRATION: FDA increasing use of data mining to detect early safety signals. "The Pink Sheet " (2005) 67(48):9.
40. SIMPSON EH: The interpretation of interaction in contingency tables. J. Royal Statist. Soc. B (1951) 13(2):238-241.
41. HARVEY JT, TURVILLE C, BARTY SM: Data mining of the Australian adverse drug reactions database: a comparison of Bayesian and other statistical indicators. Intl. Trans. Op. Res. (2004) 11:419-433.
42. MANTEL N, HAENSZEL W: Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. (1959) 22:719-748.
43. GOULD AL: Practical pharmacovigilance analysis strategies. Pharmacoepidemiol. Drug Saf. (2003) 12:559-574.
44. HAUBEN M, MADIGAN D, GERRITS CM, WALSH L, VAN PUYENBROEK EP: The role of data mining in pharmacovigilance. Expert Opin. Drug Saf. (2005) 4(5):929-948.
45. VAN PUIJENBROEK EP, EGBERTS ACG, HEERDINK ER, LEUFKENS HGM: Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. (2000) 56:733-738.
46. ALMENOFF JS, DUMOUCHEL W, KINDMAN LA, YANG X, FRAM D: Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Saf. (2003) 12:517-521.
47. DUMOUCHEL W: New Approaches to Analysis of Spontaneous ADR Databases. In: Proceedings of the Barnett Conference on Signaling Methods and Program Design. Barnett International's Educational Services, VA, USA (2004).
48. SZARFMAN A: Syndromic surveillance and risk management using Multi-item Gamma Poisson Shrinker. J. Urban Health (2003) 80(1)(Suppl.):i133.
49. VAN PUIJENBROEK EP, EGBERTS ACG, MEYBOOM RHB, LEUFKENS HGM: Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? Pharmacoepidemiol. Drug Saf. (2001) 10:135-142.
50. OGENSTAD S, HATZIS C: Drowning in information but thirsting for knowledge. Appl. Clin. Trials (2000) 9(10):46-50.
51. BANKS D, WOO EJ, BURWEN DR, PERUCCI P, BRAUN MM, BALL R: Comparing data mining methods on the VAERS database. Pharmacoepidemiol. Drug Saf. (2005) 14:601-609.
52. HAUBEN M: Trimethoprim-induced hyperkalaemia - lessons in data mining. Br. J. Clin. Pharm. (2004) 58(3):338-339.
53. KUBOTA K, KOIDE D, HIRAI T: Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol. Drug Saf. (2004) 13:387-394.
54. HAUBEN M, REICH L: Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation J. Clin. Pharmacol. (2005) 45:378-384.
55. ALMENOFF JS, LACROIX KK, YUEN NA, FRAM D, DUMOUCHEL W: Comparative performance of two quantitative safety signalling methods. Implications for use in a pharmacovigilance department Drug Saf. (2006) 29(10):875-887.
56. ROLKA H, BRACY D, RUSSELL C, FRAM D, BALL R: Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. Statist. Med. (2005) 24:551-562.
57. ROUX E, THIESSARD F, FOURRIER A, BÉGAUD B, TUBERT-BITTER P: Spontaneous reporting system modelling for data mining methods evaluation in pharmacovigilance. Intelligent Data Analysis in Medicine and Pharmacology (IDAMAP) Workshop. Cyprus, (2003).
58. HAND DJ, BLUNT G, KELLY MG, ADAMS NM: Data mining for fun and profit. Statistical Science (2000) 15(2):111-126.
59. MATTHEWS R: Storks Deliver Babies (p = 0.008). Teaching Statistics (2000) 22(2):36-38.
60. DUMOUCHEL W, SMITH ET, BEASLEY R et al.: Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin. Ther. (2004) 26(7):1092-1104.
61. SOLOMON R, DUMOUCHEL W: Contrast media and nephropathy findings from systematic analysis and food and drug administration reports of adverse effects Invest. Radiol. (2006) 41(8):651-660.
62. BREWSTER W, GIBBS T, LACROIX K, MURRAY A, TYDEMAN M, ALMENOFF J: Evolving paradigms in pharmacovigilance. Curr. Drug Saf. (2006) 1:127-134.
63. MEYBOOM RHB, LINDQUIST M, EGBERTS ACG, EDWARDS IR: Signal selection and follow-up in pharmacovigilance. Drug Saf. (2002) 25(6):459--465.
64. FOOD AND DRUG ADMINISTRATION: CDER Report to the Nation. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), USA (2005).
65. FOOD AND DRUG ADMINISTRATION: Annual Adverse Drug Experience Report 1996. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Epidemiology and Biostatistics Division of Pharmacovigilance and Epidemiology Surveillance and Data Processing Branch, USA October (1997).
66. ROSSI AE, KNAPP DE: Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. JAMA (1984) 252(8):1030-1033.
67. TRONTELL AE: How the US Food and Drug Administration Defines and Detects Adverse Events. Curr. Therap. Res. (2001) 62(9):641-649.
68. ZHOUW, POOL V, ISKANDER JK et al.: Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - Unites States, 1991-2001. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Reports Surveillance Summaries (2003)
69. 52(SS-1):1-24.
70. FOOD AND DRUG ADMINISTRATION: Medical Device Reporting. Code of Federal Regulations (2006), Title 21 Part 803.
71. LINDQUIST M: The WHO Programme for International Drug Monitoring: The Present and Future. In: Electronic Communication Technologies: A Practical Guide for Healthcare Manufacturers. Mitchard M (Ed.), CRC Press, Boca Raton, FL, USA (1998):527-549.
72. EDWARDS IR, OLSSON S: The WHO International Drug Monitoring Programme. In: Side Effects of Drugs, Annual 25. Aronson JK (Ed.), Elsevier Science BV, Amsterdam (2002):589-598.
73. EUROPEAN COMMISSION: Directive 2001/20/EC of the European Parliament and of the Council. Official Journal of the European Communities (2001) L121:34-44
74. EUROPEAN COMMISSION, DIRECTORATE ENTERPRISE, REGULATORY FRAMEWORK AND MARKET AUTHORISATIONS: Pharmacovigilance - Medicinal Products for Human use and Veterinary Medicinal Products. Rules Governing Medicinal Products in the European Union (2004) 9A.
75. BROSCH S: MedDRA and Pharmacovigilance in the EEA. Proceedings of the MedDRA MSSO Users Group Meeting. Philadelphia, USA (2006).